Clinical trials
Cancer Risk clinical trials
Below are recruiting cancer risk clinical trials, each written for real people, not researchers. We’re tracking 718 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07244094Recruiting
AI predicts breast cancer spread risk from tissue scans
This trial uses artificial intelligence to analyze images of your tumor tissue to predict if breast cancer might spread to other parts of the body. It may help doctors better understand your individual risk and guide treatment decisions.
Changchun, JilinAges 18–95 - NCT06287541Recruiting
Do you need a second bladder surgery after a negative urine test?
This study looks at whether a second bladder surgery is still needed for people with high-risk bladder cancer who had a negative urine test after their first surgery.
Nanjing, JiangsuAges 18 years+ - NCT07226544RecruitingPhase 2
Ivonescimab before surgery for high-risk kidney cancer
This trial tests giving the drug ivonescimab before surgery for patients with high-risk clear cell kidney cancer. The goal is to see if it can help shrink the tumor and improve outcomes.
Duarte, CaliforniaAges 18 years+ - NCT07036731Recruiting
Urine test study for second bladder surgery
This trial compares the need for a second surgery for people with early-stage bladder cancer. It uses a simple urine test to see if the test can help decide whether a second operation is necessary, which could save some patients from an extra procedure.
Nanjing, JiangsuAges 18–80 - NCT06732388RecruitingPhase 2
Itraconazole with ablation to prevent esophageal cancer in Barrett's esophagus
This trial tests if adding the antifungal drug itraconazole to standard ablation therapy can help prevent esophageal cancer in people with high-risk Barrett's esophagus. You must have a confirmed diagnosis of Barrett's esophagus with low- or high-grade dysplasia or early-stage cancer, and be planning to have ablation treatment.
Kansas City, KansasAges 18 years+ - NCT06280508RecruitingPhase 2
Perioperative chemo plus immunotherapy for bile duct cancer
This trial tests a combination of chemotherapy, immunotherapy (adebrelimab), and a targeted therapy (apatinib) before and after surgery for bile duct cancer that can be removed and has a high risk of coming back. It aims to see if this approach can lower the chance of recurrence.
Guangzhou, China/GuangdongAges 18 years+ - NCT06470750Recruiting
Home care for prostate cancer in Black men
This study looks at whether giving some prostate cancer care at home can help Black men and other patients who have trouble getting to the clinic. It tests if home-based care for treatments like hormone therapy, oral pills, or chemotherapy is practical and helps reduce health care gaps.
Jacksonville, FloridaAges 18 years+ - NCT06995677RecruitingPhase 2
TYRA-300 pill for low-grade bladder cancer with FGFR3 change
This study tests an experimental pill called TYRA-300 for people with low-grade bladder cancer that hasn't spread into the muscle layer. The pill targets a specific gene change (FGFR3) found in the tumor. The goal is to see if it can slow or shrink the cancer.
Homewood, AlabamaAges 18 years+ - NCT06919965RecruitingPhase 3
TAR-210 vs. standard bladder chemo for high-risk bladder cancer
This trial compares a new drug called TAR-210, given directly into the bladder, to standard chemotherapy for people with a specific type of high-risk bladder cancer that has not invaded muscle. It tests if TAR-210 can be more effective with fewer side effects.
Sun City, ArizonaAges 18 years+ - NCT07207824RecruitingPhase 3
Study of a new drug for high-risk bladder cancer
This trial tests a combination of a drug (DV) and BCG immunotherapy for people with high-risk, early-stage bladder cancer that has not spread into the muscle. The cancer must show a specific protein called HER2 on its cells.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT03250078Recruiting
Pancreatic cancer screening for people at high genetic risk
This study offers pancreatic cancer screening for people with strong family history or certain inherited gene changes. It may help find pancreatic cancer earlier, when treatment may be more effective.
Norwalk, ConnecticutAges 50–90 - NCT04472338Recruiting
Prostate cancer screening for people with higher genetic risk
This study looks at prostate cancer screening for people who may be at higher risk because of a specific inherited (genetic) change. It may help your care team find the best screening approach to catch aggressive prostate cancer earlier.
Duarte, CaliforniaAges 40 years+ - NCT04900623RecruitingPhase 2
Using HPV blood test to guide treatment for HPV throat cancer
This Phase 2 study tests a “risk-adapted” treatment plan for HPV-related throat cancer, using an HPV DNA blood test to help decide how treatment is done. If your baseline blood test shows detectable HPV DNA, the study may help tailor therapy to your risk and potentially improve outcomes while limiting unnecessary treatment.
Boston, MassachusettsAges 22 years+ - NCT05921253RecruitingEarly Phase 1
Check a brain-heart device to reduce chemo heart risk
This early-phase study tests a “neuromodulation” device (stimulating nerves that may affect the heart and blood vessels) to help lower cardiovascular risks after certain cancer chemotherapy. It may be most relevant if you recently had an anthracycline-based treatment and also have other heart-risk factors.
Oklahoma City, OklahomaAges 18–99 - NCT06291311Recruiting
Plasma treatment for cervical HPV infections
This study tests a new non-invasive plasma treatment for cervical infections caused by high- and low-risk HPV types. It may help clear the virus and prevent related health issues.
TübingenAges 18 years+ - NCT06316895Recruiting
Thermal ablation for small, low-risk thyroid cancer
This trial is studying a treatment called thermal ablation (using heat to destroy cancer cells) for people with small, low-risk papillary thyroid cancer. It aims to see how well it works and to predict outcomes.
BeijingAges 18–80 - NCT06441110RecruitingPhase 3
BCG instillation for medium- to high-risk bladder cancer
This trial tests whether a specific schedule of BCG (a weakened germ that boosts the immune system) placed directly into the bladder is safe and effective for medium- to high-risk bladder cancer that hasn't grown into the muscle. It aims to see if adjusting the standard BCG course can work better for people with a PD-L1-positive tumor.
Fuzhou, FujianAges 18–75 - NCT06533384RecruitingPhase 3
PARP inhibitor or chemo plus immunotherapy after surgery for high-risk TNBC
This trial tests whether adding a PARP inhibitor or capecitabine (chemo) to a PD-1 inhibitor (immunotherapy) after surgery helps prevent triple-negative breast cancer from coming back. It's for people with high-risk disease who have completed initial treatment.
Guangzhou, GuangdongAges 18–70 - NCT06889623Recruiting
Chemotherapy right after surgery for high-risk bladder cancer
This trial tests whether giving chemotherapy immediately after surgery can help people with high-risk, non-muscle-invasive bladder cancer. It aims to reduce the chance of the cancer coming back.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07494006Enrolling by invitation
Which breathing mode is safer during lung surgery?
This trial compares two ways of helping you breathe during lung surgery to see which one keeps your oxygen levels more stable. You will be randomly assigned to breathe either normally or with a special mode during the one-lung part of the surgery.
BeijingAges 18 years+ - NCT05572944Recruiting
Using family risk to predict lung cancer in never-smokers
This study builds and tests risk prediction tools for lung cancer in people who have never smoked, using information from family history. If it works, it may help doctors identify who might need closer screening earlier.
Taichung, TaiwanAges 20–80 - NCT06831552Recruiting
Supporting families of children with high-risk neuroblastoma
This study tests a resource intervention to help families with low income who have a child with high-risk neuroblastoma. It aims to reduce financial stress and improve care during treatment.
Hartford, ConnecticutAges Up to 17 years - NCT06872346Recruiting
Personalized follow-up after cervical cancer screening
This trial tests a personalized approach to follow-up care after cervical cancer screening. It aims to make follow-up recommendations based on your individual risk, which could help you get the right care at the right time.
Boston, MassachusettsAges 21–70 - NCT06943781Recruiting
Gastric cancer screening using high-risk gene detection
This trial is testing a new way to identify people at higher risk for stomach cancer using a gene test for Helicobacter pylori. It may help detect cancer early in people aged 40 and older.
TonglingAges 40 years+
Hear when a new Cancer Risk trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for cancer risk?
- Yes. Clin2 currently lists 718 recruiting cancer risk studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a cancer risk trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a cancer risk trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.